Alnylam Pharmaceuticals (ALNY) Competitors $246.58 +2.59 (+1.06%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALNY vs. VRTX, GILD, REGN, BIIB, UTHR, NBIX, INCY, BMRN, EXAS, and EXELShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Vertex Pharmaceuticals (NASDAQ:VRTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation. Do analysts prefer VRTX or ALNY? Vertex Pharmaceuticals currently has a consensus price target of $505.73, suggesting a potential upside of 7.77%. Alnylam Pharmaceuticals has a consensus price target of $298.09, suggesting a potential upside of 20.89%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Vertex Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vertex Pharmaceuticals 3 Sell rating(s) 9 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.55Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71 Do institutionals and insiders believe in VRTX or ALNY? 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, VRTX or ALNY? Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVertex Pharmaceuticals$10.63B11.37$3.62B-$1.99-235.80Alnylam Pharmaceuticals$2.09B15.18-$440.24M-$2.62-94.11 Does the media prefer VRTX or ALNY? In the previous week, Vertex Pharmaceuticals had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for Vertex Pharmaceuticals and 15 mentions for Alnylam Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.09 beat Alnylam Pharmaceuticals' score of 0.99 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VRTX or ALNY? Vertex Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Is VRTX or ALNY more profitable? Vertex Pharmaceuticals has a net margin of -4.52% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vertex Pharmaceuticals-4.52% -1.91% -1.43% Alnylam Pharmaceuticals -15.86%N/A -8.38% Does the MarketBeat Community favor VRTX or ALNY? Vertex Pharmaceuticals received 453 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.14% of users gave Alnylam Pharmaceuticals an outperform vote while only 75.42% of users gave Vertex Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVertex PharmaceuticalsOutperform Votes158675.42% Underperform Votes51724.58% Alnylam PharmaceuticalsOutperform Votes113376.14% Underperform Votes35523.86% SummaryVertex Pharmaceuticals beats Alnylam Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad DTIForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedMake sure to check out Gamma Pockets HERE while it’s still widely available Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.80B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-94.1110.71135.1917.53Price / Sales15.18287.971,224.59140.21Price / CashN/A56.6540.6537.95Price / Book-140.105.394.884.92Net Income-$440.24M$152.04M$118.97M$225.78M7 Day Performance-2.98%-4.32%15.53%-1.58%1 Month Performance6.16%2.80%15.54%6.67%1 Year Performance32.41%17.30%34.63%22.48% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.5509 of 5 stars$246.58+1.1%$298.09+20.9%+33.1%$31.80B$2.09B-94.112,100Short Interest ↓VRTXVertex Pharmaceuticals4.2083 of 5 stars$466.88+0.7%$505.73+8.3%+14.3%$120.24B$9.87B-233.035,400Analyst ForecastPositive NewsGILDGilead Sciences4.5372 of 5 stars$92.73+0.9%$96.43+4.0%+15.5%$115.57B$27.12B1,020.6718,000Insider TradeREGNRegeneron Pharmaceuticals4.7535 of 5 stars$733.02+0.2%$1,099.90+50.1%-13.9%$80.55B$13.12B18.1013,450Analyst ForecastBIIBBiogen4.7389 of 5 stars$151.25+0.8%$245.32+62.2%-39.3%$22.04B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7106 of 5 stars$370.95+2.5%$370.860.0%+54.1%$16.56B$2.76B16.221,168Positive NewsNBIXNeurocrine Biosciences4.8855 of 5 stars$134.00+5.8%$165.00+23.1%+13.7%$13.57B$2.24B35.791,400Analyst ForecastPositive NewsINCYIncyte4.4745 of 5 stars$70.38+2.7%$76.13+8.2%+11.4%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9834 of 5 stars$66.07+0.1%$94.20+42.6%-30.8%$12.59B$2.75B39.533,401Positive NewsEXASExact Sciences4.6099 of 5 stars$60.48-1.3%$72.94+20.6%-8.4%$11.19B$2.50B-52.356,600EXELExelixis4.5611 of 5 stars$36.01+2.8%$31.47-12.6%+48.2%$10.28B$2.08B22.461,310Analyst DowngradeShort Interest ↑ Related Companies and Tools Related Companies Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALNY) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts